B-cell NHL include a number of clinicopathologic subsets of lymphoid neoplasms having heterogeneous features. This situation is reflected by variations in the classification systems that were proposed over the last decade. Cytogenetic findings were recognized to help defining a rationale biologic ground for the nosologic classification of lymphomas. An outlook of the salient cytogenetic entities in this spectrum of disorders is presented herein; a complete illustration of the cytogenetic profile of each disease is provided in specific cards. Unless otherwise specified the WHO classification system will be used. Legend for immunophenotypes (below): +: positive in >90% of the cases; +/-: positive in more than 50% of the cases; -/+: positive in less than 50% of cases; -: positive in <10% of the cases; pan-B markers include CD19; CD20; CD79a; R = rearranged; sIg: surface immunoglobulins; cyIg: cytoplasmic Ig; IgV genes: genes encoding for the variable portion of the Ig.
Clinics and Pathology Disease
Small lymphocytic lymphoma (SLL) Phenotype / cell stem origin Histologic subset and Immunophenotype: Pan-B+; CD5+; CD23+; CD10-; sIgM+ faint.
Putative cell of origin: CD5+ virgin B-cell with germline IgV genes ( as was recently demonstrated to be the case with chronic lymphocytic leukemia, the leukemic counterpart of SLL, it is likely that part of the cases may derive from post-germinal centre quiescent B-cells that harbour hypermutated IgV genes)
Clinics
Indolent disease; leukemic involvement by lymphoid cells, including prolymphocytes and/or paraimmunoblasts Splenomegaly Cytogenetics del(6)(q21-23) (20-30% of the cases)
Disease
Lymphoplasmacytic lymphoma Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large cell lymphoma.
